Ken Mulvany talks to IBT about how the efficiency in the pharmaceutical industry can be increased by integrating AI methods.
Ken Mulvany talks to CityAm about AI, innovations and his ambitions for BenevolentAI
Our founder Ken Mulvany features in an article looking at the UK’s growing performance in AI technology and the investment the country’s industry is attracting. Ken speaks to Bloomberg’s Giles Turner about BenevolentAI's hiring spree and the 50 roles we are looking to fill.
Ken Mulvany, is interviewed by Business Insider UK in an article exploring BenevolentAI’s work to develop new drugs for diseases like Alzheimer’s and ALS.
The Financial Times takes a look at the work we’re doing at BenevolentAI to “revolutionise medical research” after speaking to Co-Founder and Director, Ken Mulvany.